Table 1.
Results from selected studies of autologous SCT in high-risk neuroblastomaa
| Group | N | Study type | EFS from | EFS | Myeloablative regimen(s) |
|---|---|---|---|---|---|
| EBMT12 | 1070 | Retrospective | Transplant | 2 year (49%) | Various |
| 5 year (33%) | |||||
| CCG 38913 | 539 | Phase III | Estimated from diagnosis | 3.7 year (38%) | CEM/TBI |
| Grupp et al.5 | 97 | Phase II | Diagnosis | 3 year (55%) | |
| No. 1 CECtx | |||||
| No. 2 melphalan/TBI | |||||
| Kletzel et al.7 | 25 | Phase II | Diagnosis | 3 year (57%) | |
| No. 1 CE | |||||
| No. 2 CE | |||||
| No. 3 TCtx | |||||
| Villablanca et al.b | 73 | Phase II | Transplant | 3 year (49%) | CEM |
| 5 year (47%) | |||||
| Kreissman et al.23 | 489 | Phase III | Diagnosis | 2 year (49%) | CEM |
| 3 year (~40%)c |
Abbreviations: C = carboplatin; CCG = Children's Cancer Group; Ctx = cyclophosphamide; E = etoposide; EBMT = European Group for Blood and Marrow Transplantation; EFS = event-free survival; M = melphalan; T = thiotepa; TBI = total body irradiation.
a
Study populations differed significantly in these six studies. The EBMT analysis included allogeneic transplants and transplants after relapse. Villablanca, et al. included only stage 4 > 1 year post-SCT in the group presented.
b
Villablanca et al., unpublished data.
c
The median follow-up on A3973 is 2 years, so this is an estimate.